FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

V	/ashir	igton,	D.C.	20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* ANDO DALE G						2. Issuer Name and Ticker or Trading Symbol SANGAMO BIOSCIENCES INC [SGMO]									all applic	•	g Perso	on(s) to Issi 10% Ow Other (s	vner
(Last) (First) (Middle) C/O SANGAMO BIOSCIENCES INC., POINT RICHMOND TECH CNTR, 501 CANAL BLVD					12	3. Date of Earliest Transaction (Month/Day/Year) 12/05/2014 4. If Amendment, Date of Original Filed (Month/Day/Year)								X Officer (give title below) VP, Therapeutic Dev. & CMO 6. Individual or Joint/Group Filing (Check Applicable					
(Street) RICHMOND CA 94804														ne) X	Form filed by One Reporti Form filed by More than O Person			·	
(City)	(S	tate)	(Zip)																
		Tab	le I - N	Non-Deri	ivativ	e Sec	curit	ies Ac	quirec	d, D	isposed o	f, or B	eneficia	ılly (Owned				
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/\)				Execution Date,		Date,	Transaction Di		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			Benefic		es ally Following	Form:	Direct Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Tra		action(s) 3 and 4)			(Instr. 4)	
Common Stock 12/05/20:			2014	M 15,000 A \$6.82 112,85		B56 ⁽²⁾⁽³⁾ D		D											
Common Stock 12/05/20			2014				S ⁽¹⁾		15,000	D	\$11.213	97,856 ⁽²⁾⁽³⁾			D				
		-	Table I								posed of, , convertil				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Executi if any			iction Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amoun or Numbe of Shares	r					
Employee Stock Option (Right to Buy)	\$6.82	12/05/2014			M			15,000	(5)		12/12/2016	Common Stock	15,00	0	\$0.00	26,798	3	D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2014.
- 2. Includes 33,333 shares, 23,333 shares, and 23,000 shares subject to restricted stock units granted on December 8, 2011, December 6, 2012, and December 12, 2013, respectively, that will be issued as such units vest in accordance with their terms.
- 3. Includes 1,277 shares acquired by the Reporting Person on October 31, 2014 under the Issuer's Employee Stock Purchase Plan.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.12 to \$11.35, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- 5. All shares underlying this option are vested and immediately exercisable.

Remarks:

/s/ Florence Tam, attorney-in-

12/09/2014

fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.